Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVERGREEN
CTR20221418Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of Ad26.RSV.preF + RSV preF protein in respiratory syncytial virus disease (RSV), respiratory syncytial virus lower respiratory tract infection, sponsored by Janssen Pharmaceutical. Started Jun 2022; status: terminated.
02
Drugs
Ad26.RSV.preF + RSV preF protein
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on CTR20221418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221418.